Gilead partners with LEO Pharma to develop inflammatory disease programs, positive.

From Investing.com: 2025-01-11 12:40:38

Gilead Sciences has partnered with LEO Pharma to develop programs for patients with inflammatory diseases. LEO Pharma could receive up to $1.7 billion, including a $250 million upfront payment. Gilead gains global rights to develop the STAT6 program targeting inflammatory conditions like atopic dermatitis. LEO Pharma may receive tiered royalties on sales of STAT6 products. The deal is expected to impact Gilead’s 2025 earnings per share by $0.15 – $0.17. Gilead aims to provide oral options for patients with chronic inflammatory conditions through this partnership.



Read more at Investing.com: Gilead, LEO Pharma partner to develop programs for inflammatory diseases By Reuters